JP2009542717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542717A5 JP2009542717A5 JP2009518610A JP2009518610A JP2009542717A5 JP 2009542717 A5 JP2009542717 A5 JP 2009542717A5 JP 2009518610 A JP2009518610 A JP 2009518610A JP 2009518610 A JP2009518610 A JP 2009518610A JP 2009542717 A5 JP2009542717 A5 JP 2009542717A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- heteroaryl
- drug
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 229940079593 drugs Drugs 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000005418 aryl aryl group Chemical group 0.000 claims 4
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000010276 construction Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims 2
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 2
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 2
- 206010038932 Retinopathy Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 229910005965 SO 2 Inorganic materials 0.000 claims 2
- 230000002253 anti-ischaemic Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000001320 atherosclerosis Diseases 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000003451 hyperinsulinaemic Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- -1 nitro, amino, cyano, methyl Chemical group 0.000 claims 2
- 200000000008 restenosis Diseases 0.000 claims 2
- 208000003432 Bone Disease Diseases 0.000 claims 1
- 206010057668 Cognitive disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010058108 Dyslipidaemia Diseases 0.000 claims 1
- 102000019622 EC 2.7.1.2 Human genes 0.000 claims 1
- 108010021582 EC 2.7.1.2 Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 102000015787 HIV Protease Human genes 0.000 claims 1
- 108010010369 HIV Protease Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 208000006132 Lipodystrophy Diseases 0.000 claims 1
- 206010024606 Lipodystrophy Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000003067 Myocardial Ischemia Diseases 0.000 claims 1
- 206010029149 Nephropathy Diseases 0.000 claims 1
- 206010029151 Nephropathy Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000005001 aminoaryl group Chemical group 0.000 claims 1
- 125000005214 aminoheteroaryl group Chemical group 0.000 claims 1
- 230000003178 anti-diabetic Effects 0.000 claims 1
- 230000002924 anti-infective Effects 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001149 cognitive Effects 0.000 claims 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000003111 delayed Effects 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000004217 heart function Effects 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000003695 memory enhancer Substances 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003449 preventive Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 CCC(*)c1c[n]c(C(*)CC)s1 Chemical compound CCC(*)c1c[n]c(C(*)CC)s1 0.000 description 7
- IOHHAJXQSHWGPW-UHFFFAOYSA-N CC(C1)(CC2)C1CP2=O Chemical compound CC(C1)(CC2)C1CP2=O IOHHAJXQSHWGPW-UHFFFAOYSA-N 0.000 description 1
- OYUDYQMFVRHPIY-UHFFFAOYSA-N CCOP(C[n](cc1)nc1NC(c1cc(Oc2ncc(C(N3CCC3)=O)nc2)cc(OC(C)C)c1)=O)(OCC)=O Chemical compound CCOP(C[n](cc1)nc1NC(c1cc(Oc2ncc(C(N3CCC3)=O)nc2)cc(OC(C)C)c1)=O)(OCC)=O OYUDYQMFVRHPIY-UHFFFAOYSA-N 0.000 description 1
Claims (16)
- 構造:
R1は、R4によって置換され、かつ1つまたは2つの置換基R5およびR6で適宜置換されたヘテロアリールであり、その中で、前記ヘテロアリールは、前記ヘテロアリール基を
R4は、
−(CH2)n−Z−(CH2)m−PO(OR7)(OR8)、
−(CH2)nZ−(CH2)m−PO(OR7)R9、
−(CH2)n−Z−(CH2)m−O−PO(OR7)R9、
−(CH2)nZ−(CH2)m−O−PO−(R9)R10、および
−(CH2)nZ−(CH2)m−PO−(R9)R10
からなる群から選択され;
R7およびR8は、同一であるかまたは異なっており、独立して選択されたアルキルであるか、あるいはR7およびR8は、環
R9およびR10は、同一であるかまたは異なっており、独立して、アルキル、アリール、アリールアルキル、ヘテロアリール、およびヘテロアリールアルキルからなる群から選択され;あるいは
R9およびR10は、環
R7およびR9は、環
に環化されてもよく;
Zは、結合、アルキレン、アルケニレン、O、SおよびSO2からなる群から選択され;
mは、0、1または2であるが、但し、Zが、O、SまたはSO2である場合に、mは、1または2であり;
nは、0、1または2であり;
R5およびR6は、同一であるかまたは異なっており、水素、アルキル、ハロゲンおよびカルボキシからなる群から選択されるか、あるいは不存在であり;
Xは、
Yが不存在である場合に、Xは、
R2は、水素、アルキル、シクロアルキル、ヘテロサイクリル、アリール、ヘテロアリール、アルキニル、およびアルケニルからなる群から選択され;
pは、0または1であり;
Qは、O、S(O)q、およびCOからなる群から選択され、ここで、qは、0、1または2であり;
Q1は、水素およびフッ素からなる群から選択され;
R11は、水素、低級アルキル、シクロアルキル、アリール、およびヘテロアリールからなる群から選択され;
R12は、水素および低級アルキルからなる群から選択されるか、あるいはR11およびR12は、それらに結合する炭素原子と共に5〜7個の炭素原子のシクロアルキル環を形成し;
R13は、ハロ、ニトロ、アミノ、シアノ、メチル、トリフルオロメチル、ヒドロキシ、メトキシ、トリフルオロメトキシ、メチルチオ、メチルスルフィニル、およびメチルスルホニルからなる群から選択され;
Tは、アリールおよびヘテロアリールからなる群から選択され;
Yは、R3−(CH2)s−であるかまたは不存在であり;
R3は、アリールおよびヘテロアリールからなる群から選択され;
sは、0または1である]
を有する化合物、すべてのその立体異性体、そのプロドラッグエステル、またはその医薬的に許容される塩。 - R4が、(CH2)n−Z−(CH2)m−PO(OR7)(OR8)であり、その中で、Zは、アルキレンまたはアルケニレンであり;
R4が、−(CH2)n−Z−(CH2)m−PO−(OR7)(OR8)であり、その中で、Zは結合であり、nは1または2であり;
R4が、−(CH2)n−Z−(CH2)m−PO−(OR7)R9であり、その中で、Zは結合であり、nは1または2であり;あるいは
R4が、−(CH2)n−Z−(CH2)m−OPO−(OR7)R9であるか、またはR4が、−(CH2)n−Z−(CH2)m−O−PO−(R9)R10であり、その中で、ZはOであり;並びに
mが、1または2である、請求項1の化合物。 - Yが、アリールまたはヘテロアリールであり;並びに
R5およびR6が、各々Hである、請求項1の化合物。 - 請求項1の化合物を単独で、または抗糖尿病薬、血糖降下薬、高インスリン血症治療薬、網膜症治療薬、神経障害治療薬、腎症治療薬、アテローム性動脈硬化症治療薬、抗感染症薬、抗虚血薬、降圧薬、抗肥満薬、脂質代謝異常治療薬、高脂血症治療薬、高トリグリセリド血症治療薬、高コレステロール血症治療薬、抗虚血薬、抗癌薬、細胞毒性治療薬、再狭窄治療薬、膵治療薬、高脂血症薬、食欲抑制薬、記憶増強剤、もしくは認知薬である別の治療剤と併用して含み、並びにその医薬的に許容される担体を含む医薬組成物。
- 請求項1の式Iの化合物を含む、グルコキナーゼ活性化薬療法が必要な疾患の進行の治療、予防、または緩徐化剤。
- 該疾患が、糖尿病、高血糖、耐糖能障害、インスリン耐性、高インスリン血症、網膜症、神経障害、腎障害、創傷治癒の遅延、アテローム性動脈硬化症およびその続発症、心機能の異常、心筋虚血、脳卒中、メタボリックシンドローム、高血圧症、肥満症、脂質代謝異常、高脂血症、高トリグリセリド血症、高コレステロール血症、低HDL、高LDL、非心臓性虚血、感染、癌、血管再狭窄、膵炎、神経変性疾患、脂質障害、認知障害および痴呆、骨疾患、HIVプロテアーゼ関連リポジストロフィー、並びに緑内障である、請求項10の治療、予防、または緩徐化剤。
- 請求項1の化合物を含む、II型糖尿病の治療剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81891206P | 2006-07-06 | 2006-07-06 | |
US60/818,912 | 2006-07-06 | ||
US11/769,964 | 2007-06-28 | ||
US11/769,964 US7910747B2 (en) | 2006-07-06 | 2007-06-28 | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
PCT/US2007/072708 WO2008005964A2 (en) | 2006-07-06 | 2007-07-03 | Phosphonate and phosphinate compounds as glucokinase activators |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012204945A Division JP5460800B2 (ja) | 2006-07-06 | 2012-09-18 | グルコキナーゼ活性化薬としてのホスホン酸およびホスフィン酸エステル化合物 |
JP2012204939A Division JP5460799B2 (ja) | 2006-07-06 | 2012-09-18 | グルコキナーゼ活性化薬としてのホスホン酸およびホスフィン酸エステル化合物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009542717A JP2009542717A (ja) | 2009-12-03 |
JP2009542717A5 true JP2009542717A5 (ja) | 2010-03-18 |
JP5361714B2 JP5361714B2 (ja) | 2013-12-04 |
Family
ID=38720453
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009518610A Expired - Fee Related JP5361714B2 (ja) | 2006-07-06 | 2007-07-03 | グルコキナーゼ活性化薬としてのホスホン酸およびホスフィン酸エステル化合物 |
JP2012204945A Expired - Fee Related JP5460800B2 (ja) | 2006-07-06 | 2012-09-18 | グルコキナーゼ活性化薬としてのホスホン酸およびホスフィン酸エステル化合物 |
JP2012204939A Expired - Fee Related JP5460799B2 (ja) | 2006-07-06 | 2012-09-18 | グルコキナーゼ活性化薬としてのホスホン酸およびホスフィン酸エステル化合物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012204945A Expired - Fee Related JP5460800B2 (ja) | 2006-07-06 | 2012-09-18 | グルコキナーゼ活性化薬としてのホスホン酸およびホスフィン酸エステル化合物 |
JP2012204939A Expired - Fee Related JP5460799B2 (ja) | 2006-07-06 | 2012-09-18 | グルコキナーゼ活性化薬としてのホスホン酸およびホスフィン酸エステル化合物 |
Country Status (20)
Country | Link |
---|---|
US (3) | US7910747B2 (ja) |
EP (1) | EP2059522B1 (ja) |
JP (3) | JP5361714B2 (ja) |
KR (1) | KR101375406B1 (ja) |
AR (1) | AR061858A1 (ja) |
AU (1) | AU2007269171B2 (ja) |
BR (1) | BRPI0713929A2 (ja) |
CA (1) | CA2658001C (ja) |
CL (1) | CL2007001994A1 (ja) |
CO (1) | CO6390122A2 (ja) |
EA (1) | EA015228B1 (ja) |
ES (1) | ES2449572T3 (ja) |
IL (1) | IL196226A (ja) |
MX (1) | MX2008016514A (ja) |
NO (1) | NO20085160L (ja) |
NZ (1) | NZ573734A (ja) |
PE (1) | PE20081001A1 (ja) |
SG (1) | SG173358A1 (ja) |
TW (1) | TWI418558B (ja) |
WO (1) | WO2008005964A2 (ja) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7910747B2 (en) * | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
JP5231411B2 (ja) | 2006-07-06 | 2013-07-10 | アレイ バイオファーマ、インコーポレイテッド | Aktプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン |
WO2008006025A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
EP2049500B1 (en) | 2006-07-06 | 2011-09-07 | Array Biopharma, Inc. | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
TW200902489A (en) * | 2007-03-07 | 2009-01-16 | Kyorin Seiyaku Kk | Glucokinase-activating substance |
WO2008154563A1 (en) * | 2007-06-11 | 2008-12-18 | Bristol-Myers Squibb Company | 1, 3 - dihydroxy substituted phenylamide glucokinase activators |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
SI2173723T1 (sl) | 2007-07-05 | 2011-12-30 | Array Biopharma Inc | Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
RU2486181C2 (ru) | 2007-07-05 | 2013-06-27 | Эррэй Биофарма Инк. | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ |
CN106279283A (zh) * | 2007-08-13 | 2017-01-04 | 症变治疗公司 | 新颖的葡糖激酶活化剂 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
ES2401685T3 (es) | 2008-01-09 | 2013-04-23 | Array Biopharma, Inc. | Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT |
KR101624753B1 (ko) | 2008-01-09 | 2016-05-26 | 어레이 바이오파마 인크. | Akt 단백질 키나제 저해물질로서의 수산화된 피리미딜 시클로펜탄 |
CN101918363B (zh) | 2008-01-18 | 2012-09-05 | 安斯泰来制药株式会社 | 苯乙酰胺衍生物 |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
KR101608259B1 (ko) | 2008-04-28 | 2016-04-01 | 교린 세이야꾸 가부시키 가이샤 | 시클로펜틸아크릴산아미드 유도체 |
UY31830A (es) | 2008-05-16 | 2010-01-05 | Takeda Pharmaceutical | Activadores de glucoquinasa |
WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
US20110021570A1 (en) | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011123572A1 (en) | 2010-03-31 | 2011-10-06 | The Scripps Research Institute | Reprogramming cells |
JP2013523894A (ja) * | 2010-04-14 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼアクチベーターおよびその使用方法 |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
CA2819381A1 (en) | 2010-10-13 | 2012-04-19 | Takeda California, Inc. | Method of making azaindazole derivatives |
ES2620644T3 (es) | 2011-04-01 | 2017-06-29 | Genentech, Inc. | Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso |
MX2013011333A (es) | 2011-04-01 | 2014-04-16 | Genentech Inc | Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso. |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
KR20140092721A (ko) * | 2013-01-16 | 2014-07-24 | 주식회사유한양행 | 신규의 헤테로아릴을 포함하는 페녹시벤즈아마이드 글루코키나제 활성화제 및 그의 제조방법 |
AU2015226855C1 (en) | 2014-03-07 | 2021-02-11 | Biocryst Pharmaceuticals, Inc. | Human plasma kallikrein inhibitors |
TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
WO2016040225A1 (en) * | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators |
CN106632298B (zh) | 2015-11-03 | 2021-06-01 | 上海科胜药物研发有限公司 | 一种泰地唑胺的制备方法及其中间体 |
WO2018017910A1 (en) | 2016-07-22 | 2018-01-25 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
US11992477B2 (en) * | 2018-05-31 | 2024-05-28 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof |
EP3823631A1 (en) | 2018-07-19 | 2021-05-26 | Astrazeneca AB | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
CN113461635A (zh) * | 2021-07-07 | 2021-10-01 | 上海毕得医药科技股份有限公司 | 4-(2-氯乙基)噻唑-2-羧酸乙酯及其制备方法和应用 |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
CA2319195A1 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
EP1062222A1 (en) | 1998-03-09 | 2000-12-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
JP4032193B2 (ja) | 1998-04-24 | 2008-01-16 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
EP1169312B1 (en) | 1999-03-29 | 2004-10-06 | F. Hoffmann-La Roche Ag | Glucokinase activators |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
TWI260321B (en) | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
AU2001287600B2 (en) | 2000-07-20 | 2006-07-13 | F. Hoffmann-La Roche Ag | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
IL144507A0 (en) | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
AU2190202A (en) | 2000-12-06 | 2002-06-18 | Hoffmann La Roche | Fused heteroaromatic glucokinase activators |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
NZ535706A (en) | 2002-04-26 | 2007-08-31 | Hoffmann La Roche | Substituted phenylacetamides and their use as glucokinase activators |
GB0218014D0 (en) | 2002-08-02 | 2002-09-11 | Eisai London Res Lab Ltd | Process |
AU2003262023A1 (en) * | 2002-09-10 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Five-membered heterocyclic compounds |
GB0226930D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
WO2004063194A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
WO2004072066A1 (en) | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
CA2516407C (en) * | 2003-02-26 | 2013-07-09 | Banyu Pharmaceutical Co., Ltd. | Heteroarylcarbamoylbenzene derivatives |
WO2005028488A1 (en) | 2003-09-12 | 2005-03-31 | Quatrx Pharmaceuticals Co. | Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels |
GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
EP1532980A1 (en) * | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
GB0328178D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
BRPI0507734A (pt) | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto |
WO2005080359A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Benzamide derivatives and their use as glucokinae activating agents |
KR20070006816A (ko) * | 2004-04-02 | 2007-01-11 | 노파르티스 아게 | 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법 |
NZ550567A (en) | 2004-04-21 | 2010-07-30 | Prosidion Ltd | Tri(cyclo) substituted amide compounds |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
US8312267B2 (en) * | 2004-07-20 | 2012-11-13 | Time Warner Cable Inc. | Technique for securely communicating programming content |
CN101035767A (zh) | 2004-08-12 | 2007-09-12 | 普洛希典有限公司 | 被取代的苯乙酰胺及其作为葡糖激酶激活剂的用途 |
GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
GB0418058D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
GB0423044D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
GB0423043D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
CA2590720A1 (en) | 2004-12-03 | 2006-06-08 | Lone Jeppesen | Heteroaromatic glucokinase activators |
EP1910350A1 (en) | 2005-07-09 | 2008-04-16 | AstraZeneca AB | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
US20080234273A1 (en) | 2005-07-09 | 2008-09-25 | Mckerrecher Darren | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes |
NZ575514A (en) * | 2005-07-09 | 2009-11-27 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
EP1915367A1 (en) | 2005-08-09 | 2008-04-30 | AstraZeneca AB | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
TW200738621A (en) | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
US7910747B2 (en) * | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
-
2007
- 2007-06-28 US US11/769,964 patent/US7910747B2/en active Active
- 2007-07-03 CA CA2658001A patent/CA2658001C/en not_active Expired - Fee Related
- 2007-07-03 EP EP07812578.8A patent/EP2059522B1/en active Active
- 2007-07-03 KR KR1020097002414A patent/KR101375406B1/ko not_active IP Right Cessation
- 2007-07-03 EA EA200900147A patent/EA015228B1/ru not_active IP Right Cessation
- 2007-07-03 SG SG2011049806A patent/SG173358A1/en unknown
- 2007-07-03 NZ NZ573734A patent/NZ573734A/en unknown
- 2007-07-03 MX MX2008016514A patent/MX2008016514A/es active IP Right Grant
- 2007-07-03 BR BRPI0713929-2A patent/BRPI0713929A2/pt not_active IP Right Cessation
- 2007-07-03 ES ES07812578.8T patent/ES2449572T3/es active Active
- 2007-07-03 WO PCT/US2007/072708 patent/WO2008005964A2/en active Application Filing
- 2007-07-03 AU AU2007269171A patent/AU2007269171B2/en not_active Ceased
- 2007-07-03 JP JP2009518610A patent/JP5361714B2/ja not_active Expired - Fee Related
- 2007-07-06 CL CL2007001994A patent/CL2007001994A1/es unknown
- 2007-07-06 TW TW096124590A patent/TWI418558B/zh not_active IP Right Cessation
- 2007-07-06 AR ARP070103051A patent/AR061858A1/es not_active Application Discontinuation
- 2007-07-06 PE PE2007000881A patent/PE20081001A1/es not_active Application Discontinuation
-
2008
- 2008-12-11 NO NO20085160A patent/NO20085160L/no not_active Application Discontinuation
- 2008-12-28 IL IL196226A patent/IL196226A/en not_active IP Right Cessation
-
2009
- 2009-01-05 CO CO09000418A patent/CO6390122A2/es active IP Right Grant
-
2011
- 2011-01-24 US US13/012,351 patent/US8153677B2/en active Active
-
2012
- 2012-02-15 US US13/397,123 patent/US8614332B2/en active Active
- 2012-09-18 JP JP2012204945A patent/JP5460800B2/ja not_active Expired - Fee Related
- 2012-09-18 JP JP2012204939A patent/JP5460799B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009542717A5 (ja) | ||
JP2010529203A5 (ja) | ||
JP2014518853A5 (ja) | ||
JP2019517487A5 (ja) | ||
JP2011527334A5 (ja) | ||
JP2009533410A5 (ja) | ||
JP2011528362A5 (ja) | ||
JP2010516701A5 (ja) | ||
JP2010516700A5 (ja) | ||
JP2013500314A5 (ja) | ||
RU2011153772A (ru) | Фторированные аминотриазольные производные | |
CA2798610A1 (en) | Bicyclic heteroaryl compounds as gpr119 modulators | |
CA2674436A1 (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
JP2010534722A5 (ja) | ||
RU2006138426A (ru) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой | |
JP2012507566A5 (ja) | ||
JP2008007519A5 (ja) | ||
JP2007506680A5 (ja) | ||
JP2020512337A5 (ja) | ||
JP2007531764A5 (ja) | ||
JP2006516251A5 (ja) | ||
JP2016500063A5 (ja) | ||
JP2010526807A5 (ja) | ||
JP2008524218A5 (ja) | ||
CA2710409A1 (en) | 6h-dibenz0 [b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists |